Supplementary Tables 1-6 from A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

Supplementary Table 1: Patient demographics. Supplementary Table 2: T cell response rates by arm. Supplementary Table 3: Peptide-specific immune response by HLA type. Supplementary Table 4: Number of patients in each group defined by sex, visceral disease and ECOG PS. Supplementary Table 5: Predicted 1-year OS rate (using Korn method) and observed 1-year OS rate for E1602 patients. Supplementary Table 6: treatment related toxicity.